{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:43:32Z","timestamp":1771307012217,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2019.00070","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T07:00:35Z","timestamp":1553842835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria"],"prefix":"10.3389","volume":"7","author":[{"given":"Konstantin","family":"Tachkov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kamusheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Mitov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miglena","family":"Doneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenka","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma receiving obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"22","author":"Cheson","year":"2018","journal-title":"J Clin Oncol."},{"key":"B2","unstructured":"K\u00f8benhavnUdgivet af SundhedsstyrelsenPakkeforl\u00f8b for H\u00e6matologiske Kr\u00e6ftformer2016"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.17650\/1818-8346-2014-9-4-15-23","article-title":"Chronic lymphoproliferative diseases: survival in cohort study of 310 patients (single-center study results and literature data)","volume":"9","author":"Pop","year":"2014","journal-title":"Oncohematology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1182\/blood-2010-12-283093","article-title":"Malignant hematologic diseases in adolescents and young adults","volume":"117","author":"William","year":"2011","journal-title":"Blood."},{"key":"B5","first-page":"151","article-title":"Hematological malignancies: disease pathophysiology of leukemic stem cells","volume":"8","author":"Ramdass","year":"2013","journal-title":"J Stem Cells."},{"key":"B6","first-page":"548","article-title":"Emerging targets for hematological malignancies","volume":"13","author":"Cilloni","year":"2010","journal-title":"Curr Opin Drug Discov Devel."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/jim-2018-000807","article-title":"New and emerging therapies for acute myeloid leukaemia","volume":"66","author":"Davis","year":"2018","journal-title":"J Investig Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14728222.2018.","article-title":"Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas","volume":"22","author":"Orlova","year":"2018","journal-title":"Expert Opin Ther Targets."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/jamaoncol.2018.1915","article-title":"Progress and innovations in the management of adult acute lymphoblastic leukemia","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3727\/000000003772462298","article-title":"Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy","volume":"14","author":"Smith","year":"2014","journal-title":"Oncol Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/leu.2014.244","article-title":"Novel drugs for older patients with acute myeloid leukemia","volume":"29","author":"Montalban-Bravo","year":"2015","journal-title":"Leukemia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/phar.1509","article-title":"Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia","volume":"34","author":"Chung","year":"2014","journal-title":"Pharmacotherapy."},{"key":"B13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10147-015-0826-3","article-title":"Current therapeutic strategies for multiple myeloma","volume":"20","author":"Torimoto","year":"2015","journal-title":"Int J Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia."},{"key":"B15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/CEOR.S114524","article-title":"Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with CLL in Spain","volume":"21","author":"Casado","year":"2016","journal-title":"ClinicoEconom Outcomes Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/CEOR.S97319","article-title":"Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey","volume":"8","author":"Ponzetti","year":"2016","journal-title":"ClinicoEconom Outcomes Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.clinthera.2016.02.005","article-title":"Cost-effectivenessof first-line chronic lymphocytic leukemia treatments when full-dose fludarabine is unsuitable","volume":"38","author":"Soini","year":"2016","journal-title":"Clin Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.18553\/jmcp.2017.23.2.214","article-title":"Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency","volume":"23","author":"Latremouille-Viau","year":"2017","journal-title":"J Manag Care Spec Pharm."},{"key":"B19","year":"","journal-title":"Health Insurance Law, Amendments Gov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"A444","DOI":"10.1016\/j.jval.2015.09.1099","article-title":"Rituximab Sc Vs rituximab iv for non-hodgkin's lymphomas (Nhls): an economic evaluation for the greek healthcare system","volume":"18","author":"Athanasakis","year":"2015","journal-title":"Value Health."},{"key":"B21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2352-302630062-X","article-title":"Economic burden of malignant blood disorders across Europe: a population-based cost analysis","volume":"3","author":"Burns","year":"2016","journal-title":"Lancet Haematol."},{"key":"B22","unstructured":"Sofia 2017Yearly Report About the Activities of the NHIF for 2016.2017"},{"key":"B23","unstructured":"Government NewspaperDecision No RD-NC-04-24-1\/29.2016"},{"key":"B24","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/blood.V120.21.4709.4709","article-title":"Health-related quality of life in hematological malignancy patients in northwestern turkey","volume":"120","author":"Pamuk","year":"2012","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1038\/bcj.2015.29","article-title":"Haematological cancer and quality of life: a systematic literature review","volume":"5","author":"Allart-Vorelli","year":"2015","journal-title":"Blood Cancer J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5937\/hpimj1402093K","article-title":"Targeted therapy and its availability in Serbia","volume":"1","author":"Kova\u010devi\u0107","year":"2014","journal-title":"Hosp Pharmacol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpubh.2019.00070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T09:01:16Z","timestamp":1574413276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpubh.2019.00070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":26,"alternative-id":["10.3389\/fpubh.2019.00070"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2019.00070","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,29]]},"article-number":"70"}}